Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine for Cognitive Functioning in Remitted Depression
NCT02016261Phase 4Completed
- Sponsor
- Moscow Research Institute of Psychiatry
- Start
- Dec 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fluvoxamine in recurrent depressive disorder (RDD), sponsored by Moscow Research Institute of Psychiatry. Started Dec 2013; status: completed.
02
Drugs
fluvoxamine
03
Conditions
recurrent depressive disorder (RDD)
Beyond the preview
Go deeper on NCT02016261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016261.